Cancer Research & Treatment Fund, Inc.

Cancer Research & Treatment Fund, Inc. The official page of Cancer Research & Treatment Fund. Please follow us to receive our latest news. In 2012, CR&T began funding the Richard T. Silver.

The Cancer Research and Treatment Fund (CR&T) is a driving force in cancer research and treatment. Founded in 1968, we are a not-for-profit fund that is committed to the belief that advances in blood cancer research lead to important breakthroughs, and a better understanding of the biology and treatment of all forms of cancer. In 2000, CR&T and the generosity of donors were instrumental in the est

ablishment of the Center for the Study of Leukemia and Myeloproliferative Neoplasms at Weill Cornell Medical College, a leading institution for cancer research. More recently, we have been involved with the breakthrough discoveries of Gleevec and now the JAK2 enzyme cancer marker . Silver Myeloproliferative Neoplasm Center at Weil Cornell Medical College, the successor to the Center for the Study of Leukemia and Myelproliferative Neoplasms at Weill Cornel Medical College. The center was dedicated in a special ceremony on February 18, 2014, and will serve as a translational research and treatment center, engaging in cutting edge discoveries surrounding MPNs. CR&T played a pivotal role in establishing the Silver MPN Center. In addition to contributing a $3.7 million gift, the Center is named after CR&T’s founder, Dr. Richard T. Dr. Andrew Schaefer, former Chairman of the Department of Medicine at Weill Cornell Medical College, has been appointed as the Center’s Director. We have achieved these successes by aggressively pursuing biological, pharmacological and molecular solutions to understand cancer, and to design drugs and diagnostic tools based on new knowledge—providing critical resources for a multidisciplinary approach that offers the greatest promise against all forms of cancer. For more than three decades, CR&T has been a major source of financial support for researchers on the frontlines of clinical cancer research at Weill Medical College of Cornell University, located at New York-Presbyterian Hospital. We have also awarded grants for research at Johns Hopkins University Medical Center, MD Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center.

It is with deep sadness that we share that our founder, Dr. Richard T. Silver, passed away peacefully at the age of 97.A...
04/20/2026

It is with deep sadness that we share that our founder, Dr. Richard T. Silver, passed away peacefully at the age of 97.

A temple service will be held on Monday, April 20th at 10:30AM at Temple Emanu-El, 1 East 65th Street (5th Avenue), New York, NY 10065. Temple Emanu-El will be offering a livestream of the funeral service, which will begin at approximately 10:25 AM on Monday. You are warmly invited to join via the link below.
https://emanuelnyc.org/worship/livestream/

Dr. Silver lived an extraordinary life defined by compassion, purpose, and an unwavering commitment to others. A pioneer in the field of medicine—particularly in the fight against blood cancer—his research and clinical work touched countless lives and helped shape the course of care for generations of patients. Beyond his remarkable professional achievements, he was a humanitarian at heart, dedicating himself not only to advancing science but to caring for each individual with dignity, empathy, and hope.

Those who had the privilege of knowing him witnessed a life led with integrity, brilliance, and profound kindness. His legacy will endure not only through his contributions to medicine, but through the many lives he changed, the patients he comforted, the students he mentored, and the inspiration he leaves behind.

We keep his family in our thoughts during this difficult time. We are indescribably grateful for his work in founding CR&T and look forward to continuing his legacy.

Memorial donations can be made at crt.org.

Polycythemia Vera (PV) is the most common type of MPN cancer. As we work with researchers tirelessly seeking a cure, we ...
04/17/2026

Polycythemia Vera (PV) is the most common type of MPN cancer. As we work with researchers tirelessly seeking a cure, we also watch patients manage this slow-moving, long-term disease that requires a marathon of medical care.

PV In Focus events offer those patients much-needed mental health and self-advocacy tools, alongside treatment information and key patient perspectives. Learn more about these free events, below!

Congratulations to CR&T Board Member Kasia McCormick on her appointment to the board of The New York Pops! Kasia was CR&...
04/16/2026

Congratulations to CR&T Board Member Kasia McCormick on her appointment to the board of The New York Pops! Kasia was CR&T's 2025 Richard T. Silver, M.D. Humanitarian Award winner for a reason—her passion for community work is as inspiring as it is impactful. We are so proud of everything she has accomplished! We know she will bring the same drive to the New York Pops.

Clinical trials are key to advancing care for people living with MPNs. At the Silver MPN Center, patients have access to...
03/25/2026

Clinical trials are key to advancing care for people living with MPNs. At the Silver MPN Center, patients have access to innovative trials that help define tomorrow’s therapies. Participation helps science AND patient care.

A gift to CR&T has the potential to truly change the lives of those battling MPN's. No gift is too small to make a chang...
03/24/2026

A gift to CR&T has the potential to truly change the lives of those battling MPN's. No gift is too small to make a change. https://www.crt.org/donate/

Symptoms of MPNs can vary widely—everything from fatigue to itching or abdominal fullness. If something feels “off,” tru...
03/23/2026

Symptoms of MPNs can vary widely—everything from fatigue to itching or abdominal fullness. If something feels “off,” trust your instincts and talk to your care team. Education empowers action.

Being diagnosed with a Myeloproliferative Neoplasm (MPN) is not just a physical journey—it’s an emotional one too. From ...
03/17/2026

Being diagnosed with a Myeloproliferative Neoplasm (MPN) is not just a physical journey—it’s an emotional one too. From the moment you hear those words, you’re not just dealing with a health condition, but with the mental and emotional weight of what lies ahead. It’s completely normal to feel overwhelmed, sad, or even angry as you process this new reality. YOU ARE NOT ALONE!

If you or someone you know is going through this, let's continue the conversation—sharing our feelings and experiences can help us all feel a little less alone.

03/14/2026

2026 Global MPN Patient Unmet Needs Assessment is now open!

MPN Research Foundation invites individuals living with a myeloproliferative neoplasm (MPN) to participate in the 2026 Global MPN Patient Unmet Needs Assessment.

This global effort helps us better understand patient experiences, priorities, and unmet needs from around the world. Healthcare access, treatments, and support can vary widely, and global participation is essential to ensure all voices are represented.

Topics include:
• MPN diagnosis & monitoring
• Therapies & clinical trials
• Symptoms & related conditions
• Access to information & resources
• Emotional health & quality of life

Take the assessment here: https://www.tfaforms.com/5184100

Preview highlights from the 2024 assessment: https://mpnresearchfoundation.org/mpn-unmet-needs-assessment-preview/

Preliminary results will be shared in Summer 2026

Please share widely — especially with international communities — to help identify unmet needs worldwide. 🌐

Myeloproliferative neoplasms (MPNs) are chronic blood disorders that affect how your body makes blood cells. They can in...
03/12/2026

Myeloproliferative neoplasms (MPNs) are chronic blood disorders that affect how your body makes blood cells. They can involve red cells, white cells, or platelets—and understanding this is the first step on your care journey. 💛

SAVE THE DATE! Knowledge empowers patients. Each year, CR&T hosts an International Patient Symposium to connect patients...
03/11/2026

SAVE THE DATE!

Knowledge empowers patients. Each year, CR&T hosts an International Patient Symposium to connect patients and caregivers with leading researchers and medical professionals. Educational presentations are recorded and shared with the community—because informed patients are stronger patients. 💙

Impact matters. CR&T directs more than 80% of every dollar donated toward research and education initiatives—maximizing ...
03/10/2026

Impact matters. CR&T directs more than 80% of every dollar donated toward research and education initiatives—maximizing donor impact and accelerating scientific discovery.

Transparency. Accountability. Progress.

Address

500 E 77th Street, Ste 1001
New York, NY
10162

Opening Hours

Monday 9:30am - 5:30pm
Tuesday 9:30am - 5:30pm
Wednesday 9:30am - 5:30pm
Thursday 9:30am - 5:30pm
Friday 9:30am - 5:30pm

Website

Alerts

Be the first to know and let us send you an email when Cancer Research & Treatment Fund, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Cancer Research & Treatment Fund, Inc.:

Shortcuts

Featured

Share

Category

Our Story

The Cancer Research and Treatment Fund (CR&T) is a driving force in cancer research and treatment. Founded in 1968, we are a not-for-profit fund that is committed to the belief that advances in blood cancer research lead to important breakthroughs, and a better understanding of the biology and treatment of all forms of cancer. In 2000, CR&T and the generosity of donors were instrumental in the establishment of the Center for the Study of Leukemia and Myeloproliferative Neoplasms at Weill Cornell Medical College, a leading institution for cancer research. More recently, we have been involved with the breakthrough discoveries of Gleevec and now the JAK2 enzyme cancer marker . In 2012, CR&T began funding the Richard T. Silver Myeloproliferative Neoplasm Center at Weil Cornell Medical College, the successor to the Center for the Study of Leukemia and Myelproliferative Neoplasms at Weill Cornell Medical College. The center was dedicated in a special ceremony on February 18, 2014, and serves as a translational research and treatment center, engaging in cutting edge discoveries surrounding MPNs. CR&T played a pivotal role in establishing the Silver MPN Center. In addition to contributing a $3.7 million gift, the Center is named after CR&T’s founder, Dr. Richard T. Silver. Dr. Andrew Schafer, former Chairman of the Department of Medicine at Weill Cornell Medical College, has been appointed as the Center’s Director. We have achieved these successes by aggressively pursuing biological, pharmacological and molecular solutions to understand cancer, and to design drugs and diagnostic tools based on new knowledge—providing critical resources for a multidisciplinary approach that offers the greatest promise against all forms of cancer. CR&T will mark its 50th Anniversary in 2018. For nearly 50 years, the organization has been a major source of financial support for researchers on the frontlines of clinical cancer research at Weill Medical College of Cornell University, located at New York-Presbyterian Hospital. We have also awarded grants for research at Johns Hopkins University Medical Center, MD Anderson Cancer Center, and Memorial Sloan-Kettering Cancer Center.